FORMOTEROL, A NEW LONG-ACTING BETA-2 AGONIST FOR INHALATION TWICE DAILY, COMPARED WITH SALBUTAMOL IN THE TREATMENT OF ASTHMA

被引：62

作者：

WALLIN, A ^{[1
]}

MELANDER, B ^{[1
]}

ROSENHALL, L ^{[1
]}

SANDSTROM, T ^{[1
]}

WAHLANDER, L ^{[1
]}

机构：

[1] NATL INST OCCUPAT HLTH,DIV MED,UMEA,SWEDEN

来源：

THORAX | 1990年 / 45卷 / 04期

关键词：

D O I：

10.1136/thx.45.4.259

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Sixteen patients with stable chronic asthma participated in a double blind crossover study comparing the new inhaled long acting beta2 agonist formoterol with salbutamol. Inhaled (n = 15) and oral steroid (n = 1) treatment were maintained at the same daily dose throughout the study. For four weeks the patients received either formoterol 24 μg twice daily or salbutamol 400 μg twice daily, plus additional puffs (with the same drug) when needed. Asthma symptoms, additional puffs of beta2 agonist, peak expiratory flow (PEF), and side effects were recorded daily. During treatment with formoterol the patients used fewer additional puffs of beta2 agonist, had better symptom scores, less disturbed sleep, more days without additional aerosol, and higher PEF both morning and evening than during salbutamol treatment. Thus formoterol 24 μg twice daily gave long lasting bronchodilatation and asthma symptoms were well controlled with regular twice daily administration.

引用

页码：259 / 261

页数：3

共 17 条

[11] INFLUENCE OF SLOW-RELEASE TERBUTALINE ON THE CIRCADIAN VARIATION OF CATECHOLAMINES, HISTAMINE, AND LUNG-FUNCTION IN NONALLERGIC PATIENTS WITH PARTLY REVERSIBLE AIR-FLOW OBSTRUCTION [J].